Last reviewed · How we verify
tocilizumab SC
Tocilizumab SC is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation.
Tocilizumab SC is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis.
At a glance
| Generic name | tocilizumab SC |
|---|---|
| Also known as | RoActemra/Actemra |
| Sponsor | Hoffmann-La Roche |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to the interleukin-6 receptor, tocilizumab SC prevents the activation of the interleukin-6 receptor and subsequent signaling pathways, thereby reducing inflammation and modulating the immune response. This mechanism of action is particularly useful in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
Common side effects
- Increased risk of infections
- Neutropenia
- Thrombocytopenia
- Hypersensitivity reactions
Key clinical trials
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (PHASE1)
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE1)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (PHASE1, PHASE2)
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (PHASE1)
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (PHASE2)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tocilizumab SC CI brief — competitive landscape report
- tocilizumab SC updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI